GGrantIndex
Sort

51,593 grants matching hepatitis

Role and mechanisms of excretion in manganese neurotoxicity

$580,914
Somshuvra Mukhopadhyay · University Of Texas At Austin · R01 · FY2022 · ES

HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India

$580,907
Shruti H Mehta · Johns Hopkins University · R01 · FY2012 · DA

HIV, HCV and STI Risk Associated with Nonmedical Use of Prescription Opioids

$580,906
Pedro Mateu-Gelabert · National Development And Research Institutes, Inc. · R01 · FY2015 · DA

GENE THERAPY FOR HEMOPHILIA A AND B

$580,809
Salk Institute For Biological Studies · R01 · FY2002 · HL

Neuropathogenesis of Rift Valley fever virus

$580,741
Anita K McElroy · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI

High Density Lipoprotein Biogenesis and Speciation

$580,616
Henry J. Pownall · Methodist Hospital Research Institute · R01 · FY2019 · HL

High Density Lipoprotein Biogenesis and Speciation

$580,616
Henry J. Pownall · Methodist Hospital Research Institute · R01 · FY2018 · HL

High Density Lipoprotein Biogenesis and Speciation

$580,616
Henry J. Pownall · Methodist Hospital Research Institute · R01 · FY2017 · HL

Investigating Syndecan-1 in Hepcidin Regulation and Iron Metabolism

$580,581
Philip Gordts · University Of California, San Diego · R01 · FY2024 · DK

CVD in American Indians Genetics Center

$580,560
Shelley A Cole · Texas Biomedical Research Institute · R01 · FY2015 · HL

Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure

$580,539
Babu L Tekwani · University Of Mississippi · R01 · FY2017 · AI

Metabolic control of gut-brain axis in Familial Dysautonomia

$580,528
Frances Lefcort · Montana State University - Bozeman · R01 · FY2021 · DK

Metabolic control of gut-brain axis in Familial Dysautonomia

$580,528
Valerie Copie · Montana State University - Bozeman · R01 · FY2022 · DK

Metabolic control of gut-brain axis in Familial Dysautonomia

$580,528
Frances Lefcort · Montana State University - Bozeman · R01 · FY2019 · DK

HCV Infection--Risk Factors for Progression

$580,526
Harvard University (Sch Of Public Hlth) · R01 · FY2005 · CA

Project 1: Cirrhosis-stroma-directed HCC chemoprevention with EGFR inhibition

$580,523
Yujin Hoshida · Ut Southwestern Medical Center · P50 · FY2025 · CA

Systems genetics approaches to bile acid metabolisms

$580,506
Karen Reue · University Of California Los Angeles · P01 · FY2017 · HL

Systems genetics approaches to bile acid metabolisms

$580,506
Karen Reue · University Of California Los Angeles · P01 · FY2019 · HL

Systems genetics approaches to bile acid metabolisms

$580,506
Karen Reue · University Of California Los Angeles · P01 · FY2018 · HL

Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis

$580,486
Arun J Sanyal · Virginia Commonwealth University · R01 · FY2023 · DK

Hepatocyte-derived extracellular vesicles in alcoholic liver disease

$580,403
Ariel Feldstein · University Of California, San Diego · R01 · FY2021 · AA

Social determinants of fatty liver disease and its racial/ethnic disparities: The Multi-Ethnic Study of Atherosclerosis

$580,398
Mariana Lazo Elizondo · Drexel University · R01 · FY2025 · DK

Integration of Evolution to Avoid Resistance in Structure Based Drug Design

$580,386
Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · GM

Signaling and metabolic functions of nSMase-2 in hepatic steatosis and onset of insulin resistance

$580,341
Mariana Nikolova-Karakashian · University Of Kentucky · R01 · FY2024 · DK

Modulation of internal ribosome entry by ribosomal protein RPS25

$580,275
Peter Sarnow · Stanford University · R01 · FY2018 · AI